Jan 07th 2013 - Edison Investment Research today published a report on quickview entitled "Ultra-orphan Strategy". In summary, the report says:
Gattex was approved by the FDA last month for the treatment of adult patients with short bowel syndrome (SBS), it is to be priced at an eye-watering $295,000 per patient-year, significantly higher than expected. However, estimated applicable patient numbers in the US are considerably lower at 3,000-5,000 (than previous guidance of 10,000-15,000). These two effects balance out and Gattex’s peak sales remain guided at $350m/year, suggesting one-third of market penetration, at the lower end of the new market size.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
